首页> 外文期刊>The Journal of Urology >Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.
【24h】

Validation of a prediction model for low volume/low grade cancer: application in selecting patients for active surveillance.

机译:低量/低度癌症预测模型的验证:在选择患者进行主动监测中的应用。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: We previously demonstrated that assessment of the number of positive cores, tumor length in a core, Gleason score and prostate volume significantly enhanced the accuracy of a prediction model for low volume/low grade cancer in men who had undergone extended biopsy. To determine the validity of the model, we applied it to an independent population of men with prostate cancer. MATERIALS AND METHODS: The study group included 170 men who had undergone radical prostatectomy without neoadjuvant therapy. In all cases, prostate cancer was diagnosed on only 1 positive core of a 10-core extended biopsy. We assessed the accuracy of the model, which consists of tumor length less than 2 mm, Gleason score 3+4 or less and prostate gland volume greater than 50 cc in predicting the occurrence of low volume/low grade cancer (defined as tumor volume less than 0.5 cc, no Gleason grade 4 or 5 disease, and organ confined disease). RESULTS: Of the patients 101 (59.4%) had low volume/low grade cancer. Our model usingall 3 previously mentioned variables had the highest performance, demonstrating a positive predictive value of 70.4% (88 of 125), a negative predictive value of 71.1% (32 of 45) and a diagnostic accuracy of 70.6% (120 of 170). This model performed better than a model based on tumor length only (positive predictive value, negative predictive value and diagnostic accuracy 68.1%, 57.9% and 64.7%, respectively) or a model based on tumor length and Gleason score (positive predictive value, negative predictive value and diagnostic accuracy 70.0%, 60.0% and 66.5%, respectively). CONCLUSIONS: This study validates that our model with a combination of tumor length, Gleason score and prostate volume is predictive for low volume/low grade cancer in an independent population of men who demonstrated only 1 positive core in an extended biopsy. This model can be used as a tool for selecting men for active surveillance.
机译:目的:我们先前证明,对接受了长期活检的男性进行低剂量/低等级癌症预测模型的评估,可以评估阳性核心的数量,核心中的肿瘤长度,Gleason评分和前列腺体积。为了确定模型的有效性,我们将其应用于独立的前列腺癌男性人群。材料与方法:研究组包括170例未经新辅助治疗而接受根治性前列腺切除术的男性。在所有情况下,仅在10核扩展活检中有1核被诊断为前列腺癌。我们评估了该模型的准确性,该模型由肿瘤长度小于2 mm,格里森评分小于或等于3 + 4以及前列腺腺体积大于50 cc组成,用于预测小体积/低度癌症的发生(定义为小于小于0.5 cc,没有格里森4级或5级疾病以及器官受限疾病)。结果:101名患者(59.4%)患有低容量/低等级癌症。我们的模型使用了前面提到的所有3个变量,具有最高的性能,其阳性预测值为70.4%(125为88),阴性预测值为71.1%(32为45)和诊断准确度为70.6%(120为170)。 。该模型的性能优于仅基于肿瘤长度的模型(阳性预测值,阴性预测值和诊断准确性分别为68.1%,57.9%和64.7%)或基于肿瘤长度和Gleason评分的模型(阳性预测值,阴性)预测值和诊断准确性分别为70.0%,60.0%和66.5%)。结论:这项研究证实了我们的模型结合了肿瘤长度,格里森评分和前列腺体积,可以预测在独立的男性人群中低体积/低度癌症,而在长期的活检中只有1个阳性核心。该模型可以用作选择进行主动监视的人员的工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号